Shots:

• Amgevita will be launched in 28 EU countries as well as Norway- Iceland and Liechtenstein making it 3rd EU Amgen's approved biosimilar
• EMA approved Amgevita in RA- PsA- AS- nr-axSpA- plague psoriasis- HS- non-infectious panuveitis- CD and UC in adults and CD- plague psoriasis- ERA and JIA in pediatric patients
• Amgevita is an IgG1 mAb that deactivates TNFα and is available in a prefilled syringe & pen (SureClick autoinjector) for approved dosing in multiple indications

Ref: Amgen  | Image: Contract Pharma